Platelet-activating factor (PAF)-like oxidized phospholipids: Relevance to atherosclerosis

被引:25
作者
Tokumura, A [1 ]
Sumida, T [1 ]
Toujima, M [1 ]
Kogure, K [1 ]
Fukuzawa, K [1 ]
机构
[1] Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan
关键词
platelet-activating factor; oxidized phosphatidylcholine; oxidized low density lipoprotein; atherosclerosis;
D O I
10.1002/biof.5520130106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lipid peroxidation is involved in the pathogenesis of chronic diseases including atherosclerosis. Oxidized lipoprotein has diverse biological activities and is believed to initiate atheroma formation and maturate fatty plaque. The active components of oxidized lipoproteins still remain to be clarified, but a likely candidate is the phosphatidylcholine (PC) having an sn-2-short-chain acyl group with a methyl, hydroxyl, aldehydic or carboxylic terminal. These unique PCs, formed by oxidative fragmentation of the polyunsaturated acyl group of the parent PC in liposomes, low density lipoproteins and blood plasma, induce platelet aggregation through the activation of the receptor for platelet-activating factor (PAF), due to their resemblance in structure with PAF. We have found that PAF-like lipids regulate DNA synthesis acid production of nitric oxide independently of the activation of the PAF receptor in vascular smooth muscle cells. Regulation of vascular cell function through two distinct signaling pathways mediated by PAF-like lipids provides new insight into the mechanism of induction of atherosclerosis.
引用
收藏
页码:29 / 33
页数:5
相关论文
共 50 条
  • [41] Relevance of the Platelet-activating factor system in chemical warfare agents-induced effects
    Thyagarajan, Anita
    Travers, Jeffrey B.
    Sahu, Ravi P.
    FREE RADICAL BIOLOGY AND MEDICINE, 2025, 228 : 62 - 67
  • [42] A glucose-containing ether lipid (Glc-PAF) as an antiproliferative analogue of the platelet-activating factor
    Mickeleit, M
    Wieder, T
    Arnold, M
    Geilen, CC
    Mulzer, J
    Reutter, W
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1998, 37 (03) : 351 - 353
  • [43] The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide
    Maniscalco, M
    Sofia, M
    Faraone, S
    Carratù, L
    ALLERGY, 2000, 55 (08) : 757 - 761
  • [44] Effects of platelet-activating factor and platelet-activating factor: acetylhydrolase on in vitro post-thaw boar sperm parameters
    Bathgate, R.
    Maxwell, W. M. C.
    Evans, G.
    THERIOGENOLOGY, 2007, 67 (04) : 886 - 892
  • [45] Current status of platelet-activating factor antagonists
    Curtin, ML
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (06) : 703 - 711
  • [46] Platelet-activating factor and edema surrounding meningiomas
    Hirashima, Y
    Hayashi, N
    Fukuda, O
    Ito, H
    Endo, S
    Takaku, A
    JOURNAL OF NEUROSURGERY, 1998, 88 (02) : 304 - 307
  • [47] Clinical aspects of plasma platelet-activating factor-acetylhydrolase
    Karasawa, Ken
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2006, 1761 (11): : 1359 - 1372
  • [48] Platelet-activating factor acetylhydrolases in health and disease
    Tjoelker, LW
    Stafforini, DM
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1488 (1-2): : 102 - 123
  • [49] Platelet-activating factor and normal or leukaemic haematopoiesis
    Denizot, Y
    Guglielmi, L
    Donnard, M
    Trimoreau, F
    LEUKEMIA & LYMPHOMA, 2003, 44 (05) : 775 - 782
  • [50] Activation of canine neutrophils by platelet-activating factor
    Okabayashi, Ken
    Kanai, Shuichiro
    Katakura, Fumihiko
    Takeuchi, Riku
    Yamauchi, Takashi
    Nakayama, Shunya
    Kinoshita, Rie
    Koie, Hiroshi
    Narita, Takanori
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2021, 241